<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867514</url>
  </required_header>
  <id_info>
    <org_study_id>P/2012/133</org_study_id>
    <nct_id>NCT02867514</nct_id>
  </id_info>
  <brief_title>Effect of the Transcranial Direct Current Stimulation (tDCS) on Dependent Smoking People</brief_title>
  <acronym>TabaSCo</acronym>
  <official_title>Evaluation de l'Effet de la Stimulation Transcranienne en Courant Continu Chez Les Personnes Tabagiques dépendantes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial
      Direct Current Stimulation (tDCS - 1 mA) applied to left vs right CDLPF of tobacco-dependent
      subjects compared to the application of a placebo tDCS (sham procedure) on the craving, which
      is evaluated by the item 1 of Fagerström test between day 1 and day 10. Craving is also
      evaluated 1 month post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco is the second leading cause of death worldwide. It is currently responsible for the
      death of one in 10 adults (about 5 million deaths per year) and it is the fourth disease risk
      factor in the world. Many methods to quit smoking are available but in all cases, relapse is
      a common phenomena. The main risk factor for relapse is craving. So, acting on the craving
      seems essential to modulate tobacco consumption. Many functional neuroimaging studies have
      established a neuroanatomical substrate for craving process, in particularly dorsolateral
      prefrontal cortex (DLPFC), accessible par neuromodulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in craving evaluated by item 1 of Fagerström test</measure>
    <time_frame>baseline, day 10 and 1 month post-ttt</time_frame>
    <description>before and after the 10 sessions</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tobacco Abuse Smoke</condition>
  <arm_group>
    <arm_group_label>anodal tDCS on left DLPFC (F3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS on left DLPFC (F3)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anodal tDCS on right DLPFC (F4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS on right DLPFC (F4)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial Direct Current Stimulation (tDCS)</intervention_name>
    <description>After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.</description>
    <arm_group_label>anodal tDCS on left DLPFC (F3)</arm_group_label>
    <arm_group_label>sham tDCS on left DLPFC (F3)</arm_group_label>
    <arm_group_label>anodal tDCS on right DLPFC (F4)</arm_group_label>
    <arm_group_label>sham tDCS on right DLPFC (F4)</arm_group_label>
    <other_name>EldithDC-NeuroConn Stimulator (NeuroConn Gmbh, Germany)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fagerström score ≥ 5

          -  Q-MAT score ≥ 6

          -  smoking subjects from 10 to 30 cigarettes a day

          -  right-handed subjects

          -  w/o severe progressive somatic pathology (especially tumor diseases, degenerative
             diseases)

          -  Hamilton Depression Rating Scale-17 score &lt;18

        Exclusion Criteria:

          -  pregnancy and/or lactation

          -  presence of a specific contraindication for tDCS (e.g. personal history of epilepsy,
             metallic head implant, cardiac pacemaker...)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Haffen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel Haffen, Prof</last_name>
    <phone>+33381219007</phone>
    <email>emmanuel.haffen@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magali Nicolier, PhD</last_name>
    <phone>+33381219007</phone>
    <email>mnicolier@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besancon - Service de Psychiatrie - Centre Investigation Clinique Innovation Technologique (CIC-IT808)</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel HAFFEN, MD PhD</last_name>
      <phone>+33381218154</phone>
      <email>emmanuel.haffen@univ-fcomte.fr</email>
    </contact>
    <contact_backup>
      <last_name>Magali NICOLIER, PhD</last_name>
      <phone>+33381219007</phone>
      <email>mnicolier@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel HAFFEN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Bellivier, MD PhD</last_name>
      <phone>(0)1 40 05 42 25 ext +33</phone>
      <email>frank.bellivier@inserm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tobacco</keyword>
  <keyword>craving</keyword>
  <keyword>tDCS</keyword>
  <keyword>attentional tasks</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

